CompuMed, Inc. (CMPD)
OTCMKTS · Delayed Price · Currency is USD
3.880
+0.080 (2.11%)
Sep 26, 2025, 11:26 AM EDT
CompuMed Revenue
CompuMed had revenue of $430.00K in the quarter ending March 31, 2012, with 1.42% growth. This brings the company's revenue in the last twelve months to $1.69M, up 0.47% year-over-year. In the fiscal year ending September 30, 2011, CompuMed had annual revenue of $1.68M, down -4.60%.
Revenue (ttm)
1.69M
Revenue Growth
+0.47%
P/S Ratio
2.97
Revenue / Employee
188.22K
Employees
9
Market Cap
5.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2011 | 1.68M | -81.00K | -4.60% |
| Sep 30, 2010 | 1.76M | -286.00K | -13.96% |
| Sep 30, 2009 | 2.05M | -105.00K | -4.88% |
| Sep 30, 2008 | 2.15M | -63.00K | -2.84% |
| Sep 30, 2007 | 2.22M | 102.00K | 4.82% |
| Sep 30, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2002 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 2.12M |
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
CompuMed News
- 1 year ago - CompuMed, FireStarter Collaborate to Further Shared Vision of Saving More Lives through Organ Donation and Transplantation - Accesswire
- 1 year ago - CompuMed Expands Cardiology Services to Rural and Regional Hospitals, Revolutionizing Patient Care - Accesswire
- 2 years ago - CompuMed Integrates the Techcyte Digital Pathology Reviewing Platform to Help Increase Transplanted Organs - Accesswire
- 2 years ago - CompuMed Announces Purchase of Shares held by VI Capital and Changes in the Board of Directors - Accesswire
- 2 years ago - CompuMed Announces Approval and Amendment to Reduce Authorized Shares - Accesswire
- 2 years ago - CompuMed CEO Lee Keddie Joins The Alliance National Innovation Leadership Council - Accesswire
- 2 years ago - Compumed, Inc. Announces Fiscal 2022 Annual and Fourth Quarter Results - Accesswire
- 3 years ago - CompuMed, Inc. Announces Fiscal 2022 Third Quarter Results - Accesswire